Comparison of the efficacy of olanzapine, metoclopramide and domperidonefor the symptom abolishment of chemotherapy induced breakthrough nausea andvomiting, randomized open label clinical study.

Jawaharlal Institute Of Postgraduate Medical Education and Research0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Histologically or cytologically confirmed malignant disease
•2.Chemotherapy naÃ¯ve patients
•3.Scheduled to receive intravenous either single or multiday highly emetogenetic chemotherapy regimens or moderately emetogenic chemotherapy regimens

•1.Patients with nausea in 24 h prior to beginning of chemotherapy
•2.serum creatinine of >2.0 mg/dl, serum bilirubin of >2.0 mg/dl, SGOT or SGPT values of >3 times the upper limits of normal
•3.Pregnant patients
•4.Patients on chemotherapy for leukemia.
•5.Esophageal and stomach malignancies are excluded from the study.
•6.Patients on continuous, intermittent or concomitant oral chemotherapy
•7.Patients on continuous, intermittent or concomitant oral chemotherapy or on opioid (morphine) treatment for pain control.
•8.Patients with known hypersensitivity to olanzapine, metoclopramide or domperidone,
•9.Patients with cardiac arrhythmia, history of congestive heart failure, or acute myocardial infarction within the previous 6 months.
•10.Patients with known history of CNS disease (e.g., brain metastases, seizure disorder), or treatment with any antipsychotic agents such as risperidone, quetiapine, clozapine, phenothiazine or butyrophenone for 30 days prior to or during protocol therapy.
•11.Patients with concurrent abdominal radiotherapy

发起方